Payment overview · 2025
General Payments
$129.60
7 reported records · 5 companies
Healthcare provider profile · identity verified
Douglas J Althouse, MD
Allopathic & Osteopathic Physicians|Family Medicine · MINDEN, NE · NPI 1447283601
Verified facts
What the public records show
CMS Open Payments records show Douglas J Althouse, MD received $129.60 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.00 | 31.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.62 | 22.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.84 | 16.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.71 | 15.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.43 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.60 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 625 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 73 |
| Potassium Chloride | Potassium Chloride | 477 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 53 |
| Losartan Potassium | Losartan Potassium | 417 | 53 |
| Omeprazole | Omeprazole | 409 | 48 |
| Eliquis | Apixaban | 365 | 28 |
| Gabapentin | Gabapentin | 363 | 42 |
| Sertraline Hcl | Sertraline Hcl | 318 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 40 |
| Furosemide | Furosemide | 293 | 32 |
| Lisinopril | Lisinopril | 287 | 40 |
| Metformin Hcl | Metformin Hcl | 271 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 21 |
| Simvastatin | Simvastatin | 231 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 25 |
| Carvedilol | Carvedilol | 211 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 209 | 17 |
| Mirtazapine | Mirtazapine | 191 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 159 | 20 |
| Xarelto | Rivaroxaban | 158 | 12 |
| Bumetanide | Bumetanide | 157 | 14 |
| Pregabalin | Pregabalin | 143 | 12 |
| Levetiracetam | Levetiracetam | 142 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 139 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 20 |
| Meloxicam | Meloxicam | 128 | 25 |
| Donepezil Hcl | Donepezil Hcl | 126 | 14 |
| Montelukast Sodium | Montelukast Sodium | 124 | 17 |
| Allopurinol | Allopurinol | 123 | 14 |
| Trazodone Hcl | Trazodone Hcl | 115 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | suppressed |
| Famotidine | Famotidine | 100 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | suppressed |
| Jardiance | Empagliflozin | 95 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 12 |
| Ozempic | Semaglutide | 91 | 12 |
| Spironolactone | Spironolactone | 90 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | suppressed |
| Lorazepam | Lorazepam | 84 | 11 |
| Memantine Hcl | Memantine Hcl | 84 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 82 | 16 |
| Primidone | Primidone | 82 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 15 |
| Dutasteride | Dutasteride | 79 | 14 |
| Amantadine | Amantadine Hcl | 72 | suppressed |
| Bupropion Xl | Bupropion Hcl | 72 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 72 | suppressed |
| Sotalol | Sotalol Hcl | 71 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 69 | suppressed |
| Prednisone | Prednisone | 67 | 40 |
| Alprazolam | Alprazolam | 66 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 64 | 64 |
| Buspirone Hcl | Buspirone Hcl | 64 | suppressed |
| Klor-Con M20 | Potassium Chloride | 64 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 11 |
| Topiramate | Topiramate | 62 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 52 |
| Ranolazine Er | Ranolazine | 60 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 59 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 59 | suppressed |
| Celecoxib | Celecoxib | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Finasteride | Finasteride | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Latanoprost | Latanoprost | 51 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Anastrozole | Anastrozole | 45 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Nystatin | Nystatin | 43 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Restasis | Cyclosporine | 35 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Zonisamide | Zonisamide | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 30 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 27 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nefazodone Hcl | Nefazodone Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.60 · 7 records | Novo Nordisk Inc | CAPVAXIVE, ENFLONSIA, EVENITY, GARDASIL 9, Ozempic, ROTATEQ, Rybelsus, VAXNEUVANCE, VOQUEZNA, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error